References
- Russell MA, Feyerabend C. Cigarette smoking: a dependence on high nicotine boli. Drug Metabol Rev 1978;8:29-57
- The Tobacco Advisory Group of the Royal College of Physicians. Nicotine addiction in Britain. London: The Royal College of Physicians, 2000. Available at: http://www.rcplondon.ac.uk/pubs/wp/wp_nicotine_summary.htm#contents [Last accessed 25 November 2009]
- Cigarette smoking. A slight fall in smoking prevalence. Office for National Statistics, UK, 2006. Available at: http://www.statistics.gov.uk/cci/nugget.asp?id = 866 [Last accessed 5 November 2009]
- Cahill K, Stead L, Lancaster TA. Preliminary benefit–risk assessment of varenicline in smoking cessation. Drug Saf 2009;32:119-35
- Edwards R. The problem of tobacco smoking. Br Med J 2004;328:217-19
- Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38
- PH10 Smoking cessation services: guidance. National Institute for Health and Clinical Excellence (NICE), 2008. Available at: http://guidance.nice.org.uk/PH10/NiceGuidance/pdf/English [Last accessed 25 November 2009]
- EPARs for authorised medicinal products for human use: Champix. European Medicines Agency, 2009. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/champix/champix.htm [Last accessed 4 November 2009]
- Lam S, Patel PN. Varenicline: a selective α4β2nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev 2007;15:154-61
- British National Formulary (BNF) 58. British Medical Association and Royal Pharmaceutical Society of Great Britain. London, 2009
- Gonzales, D, Rennard, SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. J Am Med Assoc 2006;296:47-55
- Jorenby DE, Hays TJ, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. J Am Med Assoc 2006;296:56-63
- Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:64-71
- Stapleton JA, Watson L, Spirling L, et al. Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-54
- Ramon JM, Bruguera I. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Publ Health 2009;6:1530-8
- Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401
- Blak BT, Hsia Y, Hards M. Deprivation and prevalence of risk factors and chronic diseases – is there a trend?. Pharmacoepidemiol Drug Saf 2009;18(S1):S224
- Keeler TE, Marciniak M, Hu TW. Rational addiction and smoking cessation: an empirical study. J Soc Econ 1999;28:633-43
- Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009;32:499-507